POEMS syndrome – a rare disease associated with monoclonal gammopathy and polyneuropathy: diagnosis and treatment

Czech version

Authors: Z. Král; Marta Krejčí; L. Pour; M. Štork; Martin Krejčí; V. Sandecká; Z. Adam
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno
Published in: Transfuze Hematol. dnes,27, 2021, No. 3, p. 226-231.
Category: Review/Educational Papers
doi: https://doi.org/10.48095/cctahd2021226

Overview

POEMS syndrome is rare disease associated with the presence of monoclonal gammopathy and polyneuropathy. Clinical symptoms are variable and may include organomegaly, endocrinopathy and skin changes among many. In this article, we present a recent overview of symptoms, diagnostic criteria and therapy of POEMS syndrome (2020).

Keywords:

POEMS syndrome

Sources

Bardwick PA, Zvaifler NJ, Gill GN, et al. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine. 1980; 59: 311–322.
Kang J, Yang F, Zhang HY, et al. POEMS syndrome associated with Castleman disease: a case report and literature review. Neuroimmunal Neuroinflammation. 2014; 1: 40–43.
Křížová J, Mazárová V, Válek J, et al. Crow-Fukase (POEMS) syndrom. Vnitř Lék. 1995; 41: 400–402.
Zemanová M. POEMS syndrom – multifokální osteosklerotický plazmocytom s polyneuropatií. Onkologická Péče. 2006; 10: 26–29.
Doubek M, Křivanová A, Adam Z. „POEMS“ syndrom: popis případu. Vnitř Lék. 1999; 45: 15–117.
Opíchalová D, Ščudla¨V, Vomáčka J, et al. Multifokální osteosklerotický plazmocytom s polyneuropatií – POEMS syndrom. Česká Revmatol. 2001; 9: 31–34.
Minařík J, Ščudla V, Bačovský J. Comparison of imaging methods in POEMS syndrome. Biomedical Pap Med Fac Univ Palacky Olomouc Czech Rep. 2012; 156: 52–57.
Minařík J, Zemanová M, Bačovský J, et al. POEMS syndrom. Vnitř Lék. 2008; 54: 566–567.
Minařík J, Ščudla V, Bačovský J, et al. Monitorování VEGF v průběhu POEMS syndromu. Transfuze Hematol Dnes. 2010; 16 (Suppl. 2): 114.
Pika T, Minařík J, Piková K, et al. Osteosklerotická forma mnohočetného myelomu a POEMS syndrom – diagnostické aspekty. Osteologický Bulletin. 2015; 20: 84.
Turčanová-Koprušáková M, Kurča A. Paraproteinemické neuropatie. Neurolog Prax. 2016; 17: 28–33.
Soubrier M, Guillon R, Dubost JJ, et al. Arterial obliteration in POEMS syndrome: possible role of vascular endothelial growth factor. J Rheumatol. 1998; 25: 813–815.
Nishi J, Arimura K, Utsunomiya A, et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman‘s disease. Br J Haematol. 1999; 104: 482–485.
Niimi H, Arimura K, Jonosono M, et al. VEGF is causative for pulmonary hypertension in a patient with crow‐ Fukase (POEMS) syndrome. Intern Med. 2000; 39: 1101–1104.
Scarlato M, Previtali SC, Carpo M, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain. 2005; 128: 1911–1920.
Kanai K, Kuwabara S, Misawa S, et al. Failure of treatment with anti‐VEGF monoclonal antibody for long‐standing POEMS syndrome. Intern Med. 2007; 46: 311–313.
Straume O, Bergheim J, Ernst P. Bevacizumab therapy for POEMS syndrome. Blood. 2006; 107: 4972–4973.
Dietrich PY, Duchosal MA. Bevacizumab therapy before autologous stem‐cell transplantation for POEMS syndrome. Ann Oncol. 2008; 19: 595.
Badros A, Porter N, Zimrin A. Bevacizumab therapy for POEMS syndrome. Blood. 2005; 106: 1135–1136.
Ohwada C, Nakaseko C, Sakai S, et al. Successful combination treatment with bevacizumab, thalidomide and autologous PBSC for severe POEMS syndrome. Bone Marrow Transplant. 2009; 43: 739–740.
Samaras P, Bauer S, Stenner‐Liewen F, et al. Treatment of POEMS syndrome with bevacizumab. Haematologica. 2007; 92: 1438–1439.
Sekiguchi Y, Misawa S, Shibuya K, et al. Ambiguous effects of anti‐VEGF monoclonal antibody (bevacizumab) for POEMS syndrome. J Neurol Neurosurg Psychiat. 2013; 84: 1346–1348.
Kanai K, Sawai S, Sogawa K, et al. Markedly upregulated serum interleukin‐12 as a novel biomarker in POEMS syndrome. Neurology. 2012; 79: 575–582.
Brown R, Ginsberg L. POEMS syndrome: clinical update. J Neurol. 2019; 266: 268–277.
Alberti MA, Martinez‐Yelamos S, Fernandez A, et al. 18F‐FDG PET/CT in the evaluation of POEMS syndrome. Eur J Radiol. 2010; 76: 180–182.
Glazebrook K, Guerra Bonilla FL, Johnson A, et al. Computed tomography assessment of bone lesions in patients with POEMS syndrome. Eur Radiol. 2015; 25: 497–504.
Dao LN, Hanson CA, Dispenzieri A, et al. Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid and myeloid findings in 87 patients. Blood. 2011; 117: 6438–6444.
Naddaf E, Dispenzieri A, Mandrekar J, et al. Thrombocytosis distinguishes POEMS syndrome from chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2015; 52: 658–659.
Dispenzieri A. POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2019; 94: 812–827.
Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long‐term outcome. Blood. 2003; 101: 2496–2506.
Ghandi GY, Basu R, Dispenzieri A, et al. Endocrinopathy in POEMS syndrome: the Mayo Clinic experience. Mayo Clin Proc. 2007; 82: 836–842.
Kumar S, Singh M, Thakur V, et al. Cutaneous manifestations as a clue to the diagnosis of POEMS syndrome. Postgrad Med J. 2018; 94: 668–669.
Caimari F, Keddie S, Lunn MP, et al. Prevalence and course of endocrinopathy in POEMS syndrome. J Clin Endocrinol Metab. 2019; 104: 2140–2146.
Glazebrook K, Guerra Bonilla FL, Johnson A, et al. Computed tomography assessment of bone lesions in patients with POEMS syndrome. Eur Radiol. 2015; 25: 497–504.
Alberti MA, Martinez‐Yelamos S, Fernandez A, et al. 18F‐FDG PET/CT in the evaluation of POEMS syndrome. Eur J Radiol. 2010; 76: 180–182.
Pan Q, Li J, Li F, et al. Characterizing POEMS syndrome with 18F‐Fludeoxyglucose positron emission tomography/computed tomography. J Nucl Med. 2015; 56: 1334–1337.
Humeniuk MS, Gertz MA, Lacy MQ, et al. Outcomes of patients with POEMS syndrome treated initially with radiation. Blood. 2013; 122: 66–73.
Suh YG, Kim YS, Suh CO, et al. The role of radiotherapy in the management of POEMS syndrome. Radiat Oncol. 2014; 9: 265–266.
Li J, Zhang W, Jiao L, et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood. 2011; 117: 6445–6449.
Saini NY, Patel RD, Varma A, et al. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol. 2019; 94: E72–E74.
Zagouri F, Kastritis E, Gavriatopoulou M, et al. Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. Leuk Lymphoma. 2014; 55: 2018–2023.
He H, Fu W, Du J, Jiang H, et al. Successful treatment of newly diagnosed POEMS syndrome with reduced‐dose bortezomib based regimen. Br J Haematol. 2018; 181: 126–128.
Gavriatopoulou M, Musto P, Caers J, European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018; 32: 1883–1898.
Khan M, Stone K, van Rhee F. Daratumumab for POEMS syndrome. Mayo Clin Proc. 2018; 93: 542–544.
Gavriatopoulou M, Ntanasis-Stathopoulos I, Fotiou D, et al. Upfront daratumumab with lenalidomide and dexamethasone for POEMS syndrome. Hemasphere. 2020; 4: e381.
Mitsutake A, Matsumoto H, Hatano K. Lenalidomide-induced ischemic cerebrovascular disease in polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome. J Stroke Cerebrovasc Dis. 2018; 27: e102–e103.
Jang HS, Parratt JDE, Tsang VHM, et al. Serum vascular endothelial growth factor (VEGF) level can be used as a diagnostic marker in POEMS syndrome. Pathology. 2018; 50: 674–676.